Skip to main content

We use cookies to understand how you use our site and to improve your experience.

This includes personalizing content and advertising.

By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.

You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.

In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Back to top

Wave Life Sciences to Host Second Quarter 2026 Financial Results Webcast and Conference Call

Wave Life Sciences will host a webcast on July 30, 2026, to discuss Q2 financial results and business updates.

Quiver AI Summary

Wave Life Sciences Ltd., a biotechnology company focused on RNA medicines, is set to hold a live webcast and conference call on July 30, 2026, at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide updates on its business. Interested participants can access the event through the company's website, where an archived version will be available afterwards. Wave Life Sciences employs its innovative PRISM® platform to develop treatments for conditions such as obesity, alpha-1 antitrypsin deficiency, and liver disease, along with programs targeting Duchenne muscular dystrophy and Huntington's disease. The company aims to revolutionize health by utilizing various RNA-targeting technologies and is headquartered in Cambridge, Massachusetts.

Potential Positives

  • Wave Life Sciences is set to provide its second quarter 2026 financial results and business updates in a live webcast, which enhances transparency and communication with investors.
  • The company is showcasing its innovative PRISM® platform, highlighting its multi-modal approach to RNA medicines, which may position it as a leader in addressing both rare and common disorders.
  • Wave's focus on significant clinical programs targeting obesity, liver disease, Duchenne muscular dystrophy, and Huntington’s disease demonstrates its commitment to addressing major health challenges.
  • The opportunity for analysts to participate in the Q&A portion of the call reflects the company's openness to engage with the investment community.

Potential Negatives

  • The press release highlights a live webcast for the company’s Q2 2026 financial results, which may imply challenges if results do not meet market expectations.
  • The focus on a broad range of programs could indicate a lack of specialization or heightened risk associated with multiple simultaneous developments.
  • By publicly sharing business updates and financial results, the company exposes itself to scrutiny that could affect investor confidence depending on the results presented.

FAQ

When is the Wave Life Sciences webcast scheduled?

The Wave Life Sciences webcast is scheduled for 8:30 a.m. ET on Thursday, July 30, 2026.

How can I access the Wave Life Sciences conference call?

The conference call can be accessed through the “Investor Events” section on the Wave Life Sciences website.

What will be discussed during the webcast?

The webcast will review the company’s second quarter 2026 financial results and provide business updates.

Will the webcast be available after the live event?

Yes, an archived version of the webcast will be available on the Wave Life Sciences website after the event.

What are Wave Life Sciences' focus areas?

Wave Life Sciences focuses on RNA medicines for obesity, liver disease, and genetic disorders like Duchenne muscular dystrophy.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.


$WVE Insider Trading Activity

WVE Insider Trades

$WVE insiders have traded $WVE stock on the open market 10 times in the past 6 months. Of those trades, 4 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $WVE stock by insiders over the last 6 months:

  • CAPITAL MANAGEMENT, L.P. RA has made 4 purchases buying 8,772,496 shares for an estimated $54,624,377 and 0 sales.
  • CHRIS FRANCIS (See Remarks) has made 0 purchases and 3 sales selling 35,077 shares for an estimated $524,918.
  • PAUL BOLNO (President and CEO) sold 10,480 shares for an estimated $140,956
  • KYLE MORAN (Chief Financial Officer) sold 3,588 shares for an estimated $48,258
  • CHANDRA VARGEESE (See Remarks) sold 3,228 shares for an estimated $43,416

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$WVE Hedge Fund Activity

We have seen 136 institutional investors add shares of $WVE stock to their portfolio, and 77 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • ADAGE CAPITAL PARTNERS GP, L.L.C. removed 13,567,784 shares (-93.1%) from their portfolio in Q1 2026, for an estimated $98,366,434
  • FMR LLC removed 9,943,222 shares (-65.7%) from their portfolio in Q1 2026, for an estimated $72,088,359
  • RA CAPITAL MANAGEMENT, L.P. added 8,772,496 shares (+48.2%) to their portfolio in Q1 2026, for an estimated $63,600,596
  • DARWIN GLOBAL MANAGEMENT, LTD. removed 7,298,421 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $52,913,552
  • LOOMIS SAYLES & CO L P removed 2,040,223 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,791,616
  • MARSHALL WACE, LLP added 1,789,882 shares (+inf%) to their portfolio in Q1 2026, for an estimated $12,976,644
  • BELLEVUE GROUP AG removed 1,485,257 shares (-99.6%) from their portfolio in Q1 2026, for an estimated $10,768,113

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$WVE Price Targets

Multiple analysts have issued price targets for $WVE recently. We have seen 9 analysts offer price targets for $WVE in the last 6 months, with a median target of $24.0.

Here are some recent targets:

  • Benjamin Burnett from Wells Fargo set a target price of $14.0 on 05/20/2026
  • Andrew S. Fein from HC Wainwright & Co. set a target price of $13.0 on 05/19/2026
  • Samantha Semenkow from Citigroup set a target price of $24.0 on 05/04/2026
  • Whitney Ijem from Canaccord Genuity set a target price of $43.0 on 04/30/2026
  • Danielle Brill from Truist Securities set a target price of $15.0 on 04/29/2026
  • Alec Stranahan from B of A Securities set a target price of $21.0 on 03/27/2026
  • Salim Syed from Mizuho set a target price of $27.0 on 03/25/2026

Full Release

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events .

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here .

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn .

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media :
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com


Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

WAVE Life Sciences Ltd. (WVE)

Due to inactivity, you will be
signed out in approximately: